BURVAQUIN
$45.00
BURVAQUIN (ceftiofur crystalline free acid) Sterile Suspension is indicated for the treatment of lower respiratory tract infections in horses caused by susceptible strains of Streptococcus equi subspecies zooepidemicus (S. zooepidemicus).
BURVAQUIN (ceftiofur crystalline free acid) Sterile Suspension is indicated for the treatment of lower respiratory tract infections in horses caused by susceptible strains of Streptococcus equi subspecies zooepidemicus (S. zooepidemicus).
BURVAQUIN (ceftiofur crystalline free acid) Sterile Suspension is indicated for the treatment of lower respiratory tract infections in horses caused by susceptible strains of Streptococcus equi subspecies zooepidemicus (S. zooepidemicus). S. zooepidemicus is the most common bacterial pathogen isolated from equine respiratory infections.1-3
BURVAQUIN is the first and only FDA-approved antibiotic for horses that offers a full course of therapy in just two doses. BURVAQUIN reduces the treatment requirements from 10 once or twice daily doses of a comparative antibiotic, such as oral trimethoprim-sulfonamide (TMS), to just two doses. This makes treating equine respiratory infections less stressful for the horse and more convenient for the veterinarian and horse owner.
First and Only Sustained-Release Antibiotic
- BURVAQUIN is the first and only antibiotic FDA-approved for horses that offers a full 10-day course of therapy in just two treatments.
Fewer Doses
- By providing 10 days of therapy in just two treatments, veterinarians can optimize compliance and convenience.
- Fewer administrations mean less potential for missed doses.
- Comparative treatments require 10 once or twice daily doses. Maintaining multiple treatments at consistent intervals can cause added stress for the horse as well as for those administering the medication. For a full course of therapy, your horse must receive the full dose at regular intervals as prescribed by a veterinarian.
Safe and Effective
- The use of BURVAQUIN provides veterinarians peace of mind, knowing they have selected a product that has been demonstrated to be both safe and effective in horses.
- BURVAQUIN is FDA-approved for use in horses and is available through veterinary prescription only.
- BURVAQUIN is the first and only antibiotic FDA-approved for horses that offers a full 10-day course of therapy in just two treatments.
Fewer Doses
- By providing 10 days of therapy in just two treatments, veterinarians can optimize compliance and convenience.
- Fewer administrations mean less potential for missed doses.
- Comparative treatments require 10 once or twice daily doses. Maintaining multiple treatments at consistent intervals can cause added stress for the horse as well as for those administering the medication. For a full course of therapy, your horse must receive the full dose at regular intervals as prescribed by a veterinarian.
Safe and Effective
- The use of BURVAQUIN provides veterinarians peace of mind, knowing they have selected a product that has been demonstrated to be both safe and effective in horses.
You must be logged in to post a review.
Related products
-
A180 100ML
$120.00Add to cartDescription
A180 100ML In cattle: Treatment of bovine respiratory illness caused by Mannheimia haemolytica, Pasteurella multocida and Histophilus somni sensitive to danofloxacin. A180 100ML For the treatment of acute bovine mastitis caused by Escherichia coli sensitive to danofloxacin. In neo-natal calves: Treatment of enteric infections caused by Escherichia coli sensitive to danofloxacinVM 42058/4000
Vet A180 (Canada)
Print Share
A180 (Canada)
This page contains information on A180 for veterinary use.
The information provided typically includes the following:
A180 Indications
Warnings and cautions for A180
Direction and dosage information for A180
A180
This treatment applies to the following species:
Beef Cattledanofloxacin mesylate sterile injectable solution
Veterinary Use Only
Description
A180 Injectable Solution is a sterile solution containing danofloxacin mesylate, a synthetic fluoroquinolone antimicrobial agent. Danofloxacin mesylate is the non-proprietary designationFigure 1. The chemical structure of danofloxacin mesylate
Each mL contains 180 mg of danofloxacin (as danofloxacin mesylate) and 2.5 mg phenol as the preservative.
A180 Indications
For the treatment of bovine respiratory disease associated with Mannheimia haemolytica and Pasteurella multocida.Dosage and Administration
Care should be taken to dose accurately. Administered dose volume should not exceed 15 mL per injection site.Single-Dose Therapy: Administer subcutaneously at 8 mg/kg of body weightas a one-time injection,
Multi-Day Therapy: Administer subcutaneously at 6 mg/kg of body weight with this treatment repeated once approximately 48 hours following the first injection
In cattle: Treatment of bovine respiratory disease caused by Mannheimia haemolytica, Pasteurella multocida and Histophilus somni sensitive to danofloxacin. For the treatment of acute bovine mastitis caused by Escherichia coli sensitive to danofloxacin.
In neo-natal calves: Treatment of enteric infections caused by Escherichia coli sensitive to danofloxacinIn cattle: Treatment of bovine respiratory disease caused by Mannheimia haemolytica, Pasteurella multocida and Histophilus somni sensitive to danofloxacin. For the treatment of acute bovine mastitis caused by Escherichia coli sensitive to danofloxacin.
In neo-natal calves: Treatment of enteric infections caused by Escherichia coli sensitive to danofloxacinIn cattle: Treatment of bovine respiratory disease caused by Mannheimia haemolytica, Pasteurella multocida and Histophilus somni sensitive to danofloxacin. For the treatment of acute bovine mastitis caused by Escherichia coli sensitive to danofloxacin.
In neo-natal calves: Treatment of enteric infections caused by Escherichia coli sensitive to danofloxacinA180 100ML A180 100ML A180 100ML A180 100ML A180 100ML A180 100ML A180 100ML A180 100ML A180 100ML A180 100ML A180 100ML
Reviews
There are no reviews yet.